PACS Group Inc. Securities Fraud Lawsuit: Opportunity for Investors
Investors in PACS Group Inc. (NYSE: PACS) have a chance to get involved in a securities fraud lawsuit, according to the Rosen Law Firm. If you purchased PACS common stock during the IPO in connection with the Company’s April 11, 2024 initial public offering, between April 11, 2024, and November 5, 2024, or in connection with the September 2024 secondary public offering, you might be eligible for compensation by the January 13, 2025 lead plaintiff deadline.
If you fall into one of these categories, you could be entitled to compensation without paying any out-of-pocket fees through a contingency fee arrangement. To participate in the PACS class action, visit the Rosen Law Firm’s website or contact Phillip Kim, Esq. toll-free for more information.
A lead plaintiff is crucial, as they represent other class members in the litigation process. Choosing qualified counsel with a successful track record is key. The Rosen Law Firm specializes in securities class actions and shareholder derivative litigation, with an impressive history of securing settlements for investors.
The lawsuit alleges that PACS engaged in various misleading practices, including submitting false Medicare claims and billing for unnecessary therapies. When this information came to light, investors supposedly suffered damages. If you want to be part of the lawsuit, make sure to take action before the January 13, 2025 deadline.
